Browse CATs

Browse CATs  internal medicine  cardiology  myocardial infarction

Diagnosis Economics Harm/ aetiology Prognosis Therapy ACE inhibitors Antithrombotic therapy Arrhythmia therapy Balloon pumps Beta-blockers Calcium-channel blockers Insulin Smoking cessation Thrombolysis PTCA

Myocardial infarction selective lidocaine was not clearly better than prophylactic lidocaine. Level of evidence 1b- Expiry Date October 2004 Myocardial infarction lidocaine is ineffective given routinely. Level of evidence 1a Expiry Date March  2003 Myocardial infarction d-sotalol may have increased death. Level of evidence 1b Expiry Date October 2003 Myocardial infarction lidocaine increases death. Level of evidence 1a Expiry Date October 2004 Myocardial infarction prophylactic amiodarone decreases mortality rates. Level of evidence 1a Expiry Date October 2004 Myocardial infarction arrhythmias: encainide and flecainide increased the risk of dying. Level of evidence 1b Expiry Date December 2004 Myocardial infarction arrhythmia: flecainide and encainide increased the risk of death. Level of evidence 1b Expiry Date December 2004 Myocardial infarction mortality differs between class of antiarrhythmic. Level of evidence 1a Expiry Date March  2003 Myocardial infarction class of antiarrhythmic agent affects mortality. Level of evidence 1a Expiry Date March  2003 Myocardial infarction bradycardia: atropine improved vital signs Level of evidence 4 Expiry Date October 2003